Medical Oncology

, Volume 15, Issue 1, pp 50–57

Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma

  • Joseph A Sparano
  • Peter H Wiernik
  • Xiaoping Hu
  • Catherine Sarta
  • David H Henry
  • Howard Ratech


Protease inhibitors are an important new class of agents for the treatment of human immunodeficiency virus (HIV) infection. The purpose of our trial was to determine the feasibility of combining the protease inhibitor saquinavir with a 96-hour continuous intravenous infusion of cyclophosphamide (800 mg/M2), doxorubicin (50mg/M2, and etoposide (240 mg/M2) (CDE) plus filgrastim in patients with non-Hodgkin's lymphoma associated with HIV infection. The effect of saquinavir on CDE-induced myelosuppression, CD4 lymphopenia, and non-hematologic toxicity was also sought. Twelve patients with HIV-related lymphoma received CDE every 28 or more days. All patients received saquinavir (600 mg PO TID), filgrastim andPneumocystis carinii and fungal prophylaxis. Patients also received either stavudine (n=2) or boths stavudine and didanosine (n=10). Toxicity was analyzed using the NCI Common Toxicity Criteria for each cycle and the data were compared with the data from our prior study of CDE plus didanosine. An interim analysis was performed after accrual of the first 12 patients in order to assess toxicity. Severe (grade 3 or 4) mucositis occurred in eight of 12 patients (67%) treated with CDE plus saquinavir compared with three of 25 patients (12%) in our prior study treated with CDE without saquinavir (P<0.001). In logistic regression analysis, saquinavir use was the only factor associated with a significantly greater risk of severe mucositis (relative risk 7.9;P=0.03). Saquinavir use was not associated with a significant difference in the incidence of febrile neutropenia, prolonged neutropenia, chemotherapy dose reduction, or in the degree of myelosuppression. The decrease in CD4 lymphocytes for patients treated with saquinavir (absolute decrease of 23/μL, or a 26% decrease from baseline) was significantly less than for patients treated without saquinavir in the prior study (absolute decrease of 91/μL, or 42% decrease from baseline;P=0.05). Four of 10 patients (40%) treated with saquinavir had an increase in CD4 lymphocytes of ≥10/μL compared with none of 25 patients (0%) treated without saquinavir (P<0.001). Combination of the protease inhibitor saquinavir with infusional CDE in patients with HIV-associated lymphoma was associated with a significant increase in the incidence of severe mucositis. This finding suggests that saquinavir may alter the metabolism of one of more of the cytotoxic agents in the CDE regimen, and underscores the need for careful investigation regarding the use of the protease inhibitors in patients receiving chemotherapy.


AIDS-associated lymphoma chemotherapy protease inhibitors saquinavir 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rabkin CS, Yellin F. Cancer incidence in a population with a high prevalence of infection with human immunodeficiency virus type 1.Natl Cancer Inst 1994;86: 1711–1716.CrossRefGoogle Scholar
  2. 2.
    Gail MHet al. Projections of the incidence of non-Hodgkin's lymphoma related to acquired immunodeficiency syndrome.J Natl Cancer Inst 1991;83: 695–700.PubMedCrossRefGoogle Scholar
  3. 3.
    Pluda JMet al.. Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy.J Clin Oncol 1993;11: 1099–1107.PubMedGoogle Scholar
  4. 4.
    Sparano JA. Treatment of AIDS-related lymphomas.Current Opinion in Oncology 1995;7: 442–450.PubMedCrossRefGoogle Scholar
  5. 5.
    Sparano JAet al. Infusional cyclophosphamide, doxorubicin, and etoposide in HIV-and HTLV-I-related non-Hodgkin's lymphoma: a highly active regimen.Blood 1993;81: 2810–2815.PubMedGoogle Scholar
  6. 6.
    Sparano JAet al. Infusional cyclophosphamide, doxorubicin and etoposide in HIV-related non-Hodgkin's lymphoma: a follow up report of a highly active regimen.Leuk Lymphoma 1994;14: 263–271.PubMedCrossRefGoogle Scholar
  7. 7.
    Sparano JAet al. Opportunistic infection and immunologic function in patients with human immunodeficiency virus-related non-Hodgkin's lymphoma treated with chemotherapy: a case control study.J Natl Cancer Inst 1997;89: 301–307.PubMedCrossRefGoogle Scholar
  8. 8.
    Sparano JAet al. A pilot trial of infusional cyclophosphamide, doxorubicin and etoposide plus didanosine and filgrastim in patients with HIV-associated non-Hodgkin's lymphoma.J Clin Oncol 1996;14: 3026–3035.PubMedGoogle Scholar
  9. 9.
    Litte Ret al. HIV viral burden during EPOCH chemotherapy for HIV-related lymphomas.J AIDS Human Retroviral 1997;14:A42 (abstr 104).Google Scholar
  10. 10.
    Bartlett JG. Protease inhibitors for HIV infection.Ann Intern Med 1996;124: 1086–1087.PubMedGoogle Scholar
  11. 11.
    Sparano JA, Sarta C. Infection prophylaxis and antiretroviral therapy in patients with HIV infection and malignancy.Curr Opin Oncol 1996;8: 392–399.PubMedCrossRefGoogle Scholar
  12. 12.
    Collier ACet al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine.N Eng J Med 1996;334: 1011–1017.CrossRefGoogle Scholar
  13. 13.
    Oken MM, Creech RH, Tormey DC. Toxicity and response criteria of the Eastern cooperative Oncology Group.Am J Clin Oncol 1982;5: 649–655.PubMedCrossRefGoogle Scholar
  14. 14.
    Rosner B.Fundamentals of Biostatistics. 1995; 4th edn. Duxbury Press: New York.Google Scholar
  15. 15.
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations.J Am Stat Assoc 1958;53: 457–481.CrossRefGoogle Scholar
  16. 16.
    SAS/INSIGHT. User's Guide. 1993; 2nd edn, version 6. SAS Institute, Inc: Cary, NC.Google Scholar
  17. 17.
    Saquinavir (Invirase®) package insert. Roche Laboratories, Nutley, NJ, 07110. 1995.Google Scholar
  18. 18.
    Indinavir (CrixivanTM) package insert. Merck & Co., West Point, PA, 19486. 1996.Google Scholar
  19. 19.
    Ritonavir (NorvirTM) package insert. Abbot Laboratories, North Chicago, IL 60064. 1996.Google Scholar
  20. 20.
    Nelfinavir (Viracept®) package insert. Agouron Pharmaceuticals, Inc., La Jolla, CA, 92037. 1997.Google Scholar
  21. 21.
    Newman EM, Doroshow JH, Forman SJ, Blume KG. Pharmacokinetics of high-dose etoposide.Clin Pharmacol Ther 1998;43: 561–564.CrossRefGoogle Scholar
  22. 22.
    Jones RBet al. A Phase I−II study of intensive-dose adriamycin for advanced breast cancer.J Clin Oncol 1987;5: 172–177.PubMedGoogle Scholar
  23. 23.
    Vogelzang N. Continuous infusion chemotherapy: a critical review.J Clin Oncol 1984;2: 1289–1304.PubMedGoogle Scholar
  24. 24.
    Sparano JAet al. Infusional cyclophosphamide, doxorubicin, and etoposide for HIV-associated non-Hodgkin's lymphoma: long-term followup and analysis of prognostic factors.J AIDS Hum Retrovirol 1987;14:A38 (abstr 88).Google Scholar

Copyright information

© Stockton Press All rights reserved 1998

Authors and Affiliations

  • Joseph A Sparano
    • 1
  • Peter H Wiernik
    • 1
  • Xiaoping Hu
    • 1
  • Catherine Sarta
    • 1
  • David H Henry
    • 3
  • Howard Ratech
    • 2
  1. 1.Department of Oncology, Albert Einstein Cancer Center, Montefiore Medical CenterAlbert Einstein College of MedicineBronxUSA
  2. 2.Department of Pathology, Albert Einstein Cancer Center, Montefiore Medical CenterAlbert Einstein College of MedicineBronx
  3. 3.Graduate HospitalPhiladelphiaUSA

Personalised recommendations